Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Cefuroxime

Cefuroxime

Second-generation cephalosporin (oral + parenteral)

CAPSSTIIVPOΞ²-lactam

Indication

CAP β€’ SSTI β€’ otitis/sinusitis (selected) β€’ Lyme arthritis (selected protocols) β€’ peri-operative prophylaxis

At a glance

INDICATIONS (CORE USE)

CAP (when local guideline supports); SSTI; some UTIs; surgical prophylaxis (protocol) β€” NOT pseudomonas.

ADULT DOSE (STANDARD)

IV: 750 mg–1.5 g q8h (infection severity); PO axetil 250–500 mg q12h

MAX DOSE

Adult IV ~6 g/day in severe infection (local max); PO axetil typically ~1 g/day

Route

IV, IM, PO (as cefuroxime axetil)

PEDIATRIC DOSE

Pediatric IV/PO per weight protocol (~50–100 mg/kg/day divided, max by indication)

Do not miss

Must-not-miss safety points

Major warning

- Ξ²-lactam anaphylaxis risk - Not anti-pseudomonal β€” gram-negative treatment failure if Pseudomonas / resistant Enterobacterales - Axetil PO bioavailability food-dependent β€” give with food - Renal adjustment for IV formulation

Indications

USE IF: Respiratory / SSTI / some UTI when second-gen spectrum matches susceptibility. AVOID IF: Pseudomonas, MRSA (unreliable), ESBL risk infections, severe cephalosporin allergy.

Primary

  • Community-acquired pneumonia (non-ICU) when guideline-appropriate and susceptibility expected
  • Acute bacterial sinusitis / otitis media (selected cases per guideline)
  • Skin/soft tissue infection due to susceptible organisms

Secondary

  • Early Lyme disease / some Lyme manifestations (ID guideline–dependent)
  • Peri-operative prophylaxis in institutions using cefuroxime-based protocols

Other

  • IVβ†’PO step-down using axetil when susceptibility confirmed

Dosing

STANDARD (ADULT PO)

IV 750 mg–1.5 g q8h OR PO axetil 250–500 mg q12h (with food)

ADULT DOSE

IV/IM: 750 mg q8h mild–moderate; 1.5 g q8h severe PO axetil: 250–500 mg q12h (give with food)

PEDIATRIC DOSE

Use pediatric references β€” weight-based IV/PO divided doses.

MAX DOSE

Adult IV up to ~4.5–6 g/day in selected severe infection (institution-specific).

Practical Note

PO axetil β‰  IV mg-for-mg β€” follow product monograph.

Warnings

Clinical warnings

  • **Ξ²-lactam allergy β€” immediate** (anaphylaxis, angioedema, bronchospasm, hypotension) β†’ **avoid** this agent; use non–β-lactam alternative
  • **Ξ²-lactam allergy β€” non-severe** (maculopapular rash without systemic anaphylaxis features) β†’ **caution**; risk/benefit + allergy/ID pathway; graded challenge or test dose **only** per protocol β€” do not dismiss automatically
  • **Neurotoxicity:** encephalopathy, confusion, myoclonus, seizures β€” **higher risk with CKD, elderly, dose accumulation** (notably cefepime, carbapenems, high-dose penicillins)
  • New CNS symptoms + renal impairment on IV Ξ²-lactam β†’ **hold dose**, check levels/exposure, rule out other causes
  • C. diff risk
  • False-positive glucose tests (some assays)
  • Seizure threshold β€” rare CNS effects at extreme doses + renal failure

Adverse effects

  • GI upset (PO)
  • injection site pain
  • rash
  • C. diff

Contraindications

  • Immediate cephalosporin anaphylaxis history when alternative required

Drug interactions

  • Probenecid β†’ ↑ levels
  • Warfarin monitoring

Special populations

Pediatrics

Pediatric IV/PO per weight protocol (~50–100 mg/kg/day divided, max by indication)

Pregnancy

Pregnancy: generally acceptable when indicated.

Lactation

low levels; usually compatible.

Renal impairment

Reduce IV dose/interval in CKD; HD dosing per pharmacy. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + institutional pharmacy nomogram):** - **CrCl β‰₯50** β†’ standard interval (per Adult dosing card) - **CrCl 10–50** β†’ extend interval and/or reduce dose (often q12–24h or ↓ dose β€” **product-specific**) - **CrCl <10** β†’ maximal interval extension / dose reduction; **HD: redose post-dialysis** per protocol; AKI β†’ re-estimate CrCl; **neuro signs** β†’ hold/adjust

Hepatic impairment

No standard adjustment.

Elderly

Renal dosing; delirium from infection vs drug β€” clinical correlation.

Administration

PO axetil with food. IV push per local policy (often intermittent infusion).

Monitoring

  • Monitor: - ICU or CKD β†’ **creatinine daily** β†’ underdosing in AKI vs accumulation / **neurotoxicity** if not adjusted - New confusion / myoclonus / seizures + renal impairment on IV Ξ²-lactam β†’ **hold dose** β†’ evaluate encephalopathy - Serious GNR infection β†’ extended-infusion / pharmacy optimization per protocol - Renal function in CKD
  • Recheck: - Clinical response CAP at 48–72h β†’ consider resistant pathogen - No clinical improvement at 48–72h β†’ reassess diagnosis, resistance, source control, and drug interactions - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

**Life-threatening (first):** **CNS toxicity** β€” seizures, encephalopathy, agitation, myoclonus, coma (**↑ CKD, elderly, accumulation**; cefepime, carbapenems, high-dose penicillins). **Allergic:** anaphylaxis / angioedema (separate pathway). **Secondary:** nausea/vomiting/diarrhea mainly with acute massive **oral** co-ingestion or local infusion reaction.

Immediate Actions

Stop Ξ²-lactam β†’ ABCs β†’ **seizure precautions**; benzos if seizures; check renal function / dose vs CrCl; anaphylaxis β†’ epinephrine + ACLS

Antidote

No specific antidote; treat complications (e.g. anaphylaxis β†’ epinephrine per ACLS)

Decontamination

Stop infusion; recent large PO load β†’ charcoal if protected airway + early presentation

Escalation

Status epilepticus, coma, refractory seizures β†’ **ICU**; **severe CNS toxicity or AKI with accumulation β†’ consider hemodialysis** for dialyzable agents β€” nephrology + pharmacy; persistent anaphylaxis β†’ ICU

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

2nd-gen bridge drug for some **respiratory** + **UTI** pathogens β€” not pseudomonas. PO give **with food**.

Clinical pearls

CAP: align with local resistance (S. pneumoniae). Stewardship: duration per guideline (sinusitis often over-treated). De-escalate IV→PO when safe. *Stewardship (all antimicrobials):* Empiric choice → syndrome severity + **local antibiogram**; shortest effective course.

Stewardship & safety

  • Food with axetil
  • Renal IV adjust
  • C. diff

Pharmacokinetics

IV/IM widely distributed; axetil is ester prodrug; renal elimination predominant.

Mechanism of action

Ξ²-lactam PBP binding β†’ cell wall synthesis inhibition.

Common brand names

Saudi Arabia

Zinacef, Ceftin

Global

(placeholder β€” verify local formulary)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Empiric choice β†’ tie to syndrome, severity, and local antibiogram β€” not habit.
  • IV β†’ PO step-down when oral bioavailability and susceptibility allow.
  • Do not use antibiotics for uncomplicated viral illness β€” stewardship.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling

Do not miss

  • Uncomplicated viral URI/bronchitis β†’ antibiotics rarely indicated
  • Narrow or stop when susceptibilities + clinical stability allow
  • Wrong spectrum for Pseudomonas / many ESBL.
  • Ξ²-lactam allergy vigilance.
  • Food with axetil
  • Renal IV adjust
  • C. diff